Protagenic Therapeutics

Protagenic Therapeutics FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Protagenic Therapeutics (PTIX) as of Nov 16, 2026 is 80.30 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 76.32 % — a change of 5.22% (higher).

FCF Conversion

80.30 %

YoY

5.22%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Protagenic Therapeutics is 2025 80.30 % . FCF Conversion Rate (FCF/EBITDA) of Protagenic Therapeutics was 2024 76.32 % . It decreases by 5.22% higher compared to the previous year.

The Protagenic Therapeutics FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
41.88 USD
Jan 1, 2019
27.87 USD
Jan 1, 2020
52.92 USD
Jan 1, 2021
61.88 USD
Jan 1, 2022
56.12 USD
Jan 1, 2023
77.07 USD
Jan 1, 2024
76.32 USD
Jan 1, 2025
80.30 USD
The Protagenic Therapeutics FCF Conversion history
YEARFCF ConversionYoY
80.30 %+5.22%
76.32 %-0.98%
77.07 %+37.33%
56.12 %-9.30%
61.88 %+16.92%
52.92 %+89.89%
27.87 %-33.45%
41.88 %-31.42%
61.07 %+21.88%
50.10 %-37.08%
79.62 %+8.61%
73.31 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Protagenic Therapeutics Stock analysis

What does Protagenic Therapeutics do? Protagenic Therapeutics, Inc. develops therapeutics for stress-related neuropsychiatric and mood disorders. Its lead compound PT00114 is a synthetic TCAP-1 peptide designed to dampen overactive stress responses. The company also has a portfolio of earlier stage neuropeptides targeting the TCAP pathway in preclinical evaluation. PT00114 has shown pre-clinical efficacy in animal models of depression, anxiety, substance abuse, addiction, and PTSD, including the Saleens test for opioid withdrawal. The company focuses on developing treatments for conditions where current therapies are limited or ineffective. Protagenic's products are developed for pharmaceutical companies and research institutions seeking novel treatments for neuropsychiatric disorders. The target segments include patients suffering from depression, anxiety, PTSD, and substance abuse disorders. The company's lead compound PT00114 and its neuropeptide portfolio are positioned as potential treatments for these conditions, with the aim of addressing unmet medical needs in mental health care. Protagenic Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Protagenic Therapeutics stock

FCF Conversion Rate (FCF/EBITDA) of Protagenic Therapeutics is 80.30 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Protagenic Therapeutics changed from 76.32 % to 80.30 %, representing a 5.22% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Protagenic Therapeutics since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Protagenic Therapeutics with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Protagenic Therapeutics

All Key Metrics — Protagenic Therapeutics